Keren Rouvinov

10PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsLiquid biopsiesSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 26, 2026
The Impact of Angiotensin-Converting Enzyme Inhibitors on Immune-Related Adverse Events and Clinical Outcomes in Patients with Metastatic NSCLC.

|Aug 26, 2026
Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) on the Efficacy of Immunotherapy in Metastatic NSCLC.

|Jun 25, 2026
Evaluating the Role of Chemotherapy in Addition to Radiotherapy for High-Risk Merkel Cell Carcinoma.

|May 27, 2026
Optimal Duration of Adjuvant Platinum-Etoposide in High-Risk Merkel Cell Carcinoma.

|Apr 24, 2026
Survival Outcomes in Lymph Node-Positive Merkel Cell Carcinoma (Stage III): A Comparison Between Known and Unknown Primary Tumors and Their Sun Exposure Sites.

|Mar 28, 2026
Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer.

Keren Rouvinov, Rashad Naamneh, Alexander Yakobson

Pageof 2

Frequent Collaborators

9 joint publications

Walid Shalata

4 joint publications

Abed Agbarya

3 joint publications

Rashad Naamneh

3 joint publications

Wenad Najjar